Postpartum Hemorrhage Clinical Trial
Official title:
Incidence and Risk Factors for Secondary Severe Postpartum Hemorrhage in the General Population
Postpartum hemorrhage (PPH) remains one of the leading causes of maternal mortality and morbidity worldwide, including in France, where it accounts for approximately 20% of maternal mortality. Although numerous studies have examined immediate PPH, very few have explored secondary (also called late) PPH. Moreover, there are no guidelines in France for the management of secondary PPH. Its frequency appears to vary from 0.2% to 3.0% of deliveries. It is, however, difficult to estimate because only severe secondary PPH will lead to hospitalization and the rare publications concern single-center studies. The cause of these secondary hemorrhages is often unknown, due to the lack of routine uterine aspiration. Nonetheless, this aspiration is not always medically justified. The principal objective of this study is thus to establish the incidence of severe late PPH in the general population.
1. Justification of the non-interventional nature of the study:
Severe late PPH is a rare disorder that can be difficult to diagnose. It is a source of
severe maternal morbidity; its management is not well defined; and the lack of knowledge
of its risk factors means that groups of women at risk of this disorder cannot be
identified. Because of the lack of scientific data, it is impossible to set up
monitoring appropriate to each woman's risk or to provide women who have just given
birth with appropriate information.
The practices studied will be those usually used in the healthcare facilities in
Auvergne that manage PPH. The data useful for this study will be those collected
routinely in medical files, but will be collected prospectively for women who are
hospitalized after a severe late PPH. Investigators conducted this type of data
collection for the Hera study (national PHRC), which covered immediate postpartum
hemorrhages, for which management is well codified through the national good clinical
practice guidelines, updated in 2014 .The section on the management of secondary
hemorrhages shows the sparseness of the relevant scientific data on this subject. The
guidelines are thus based mainly on expert opinion. Accordingly, the value of this study
is that it will begin to develop an evidence base for the management of this disorder.
The guidelines specify that "the management of late PPH depends on their cause and their
severity [antibiotic therapy (Grade A) and uterotonic agents (professional consensus)].
This treatment must follow the hospital's own protocols (professional consensus). Most
often, women are admitted for this management (professional consensus). In the case of
persistence of the PPH and retention of placental fragments, aspiration-curettage under
ultrasound control or operative hysteroscopy is recommended (professional consensus). In
cases of vascular abnormalities, selective embolization is the treatment of choice
(professional consensus)." This study will not direct professionals to use any specific
rules or practices for the management of these late hemorrhages, other than the national
guidelines cited above. Because of the great autonomy it offers for this management, it
probably results in substantial heterogeneity in care, which this study will observe and
examine. At the end of the study, investigator hope to have highlighted the most
relevant management practices by cause of these severe late PPH.
2. Procedure for early withdrawal from the study: the woman's refusal to participate in the
study.
3. Methods of recruitment:
Women with a severe late PPH will be recruited prospectively after verification of the
inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who
will provide the patients information about the study and include them unless they
object.
4. Steps taken to reduce and avoid bias:
Because the objective is to determine the incidence of severe late/secondary PPH,
investigator will have several investigators at each site to be able to optimize the
prospective identification of women meeting the inclusion criteria. Data entry will be
performed by a research midwife who will have access to all of the medical data sources
at each site (regional computerized pregnancy and delivery records, paper medical
records, local computerized file for surgical, laboratory, pathology and imaging
reports, hospital computerized discharge summary) to limit missing data. The aim is to
obtain an exhaustive list of severe late PPH in the general population, to be ensured by
the consultation of multiple data sources. Because these data sources are generated by
different institutions and agencies, the selection bias associated by collection from a
specific population (e.g., a single center) will be avoided.
5. Collection of data for women with a severe late PPH Patient inclusion and data
collection will take place continuously. Every case of severe late PPH among women who
give birth in the region of Auvergne will be included.
The women will be informed about the planned study and procedures by posters in the
maternity units (lounges and waiting rooms, the web site of the Auvergne perinatal
network) and by an information sheet.
At the time the case is identified, several data items will be collected immediately by
one of the local investigators (data about the late PPH episode); the other data, as
well as those concerning antenatal care during pregnancy will be collected by the
research midwife from the regional computerized records and other portions of the
woman's file, in each institution (laboratory, pathology, and surgery reports).
* Passive data collection: It will be based on the spontaneous reporting of cases by the
correspondents in each maternity unit. These lists of cases, on a specific form, will be
reported to the principal investigator monthly.
*Active data collection: A research midwife will complete the files already underway.
The investigator will visit the site to consult the woman's paper or computerized
records and complete the information then missing from the study file. Auvergne has a
regional computerized perinatal database. These site visits will be planned by the
investigator, who will telephone the local correspondent to make an appointment and
request from him or her a list of files to be made available.
The frequency of site visits will vary according to the number of patients reported by
each site.
The different modes of active data collection:
- Data collection by telephone Will cover only the minimum data necessary to open the
file or the small quantities of missing data.
- Data collection by mail The physician serving as the study director will contact
the study correspondents, if necessary, once a quarter to review the number of
women with late PPH at each facility. Investigators will check the data for each
case and open new files when applicable.
- Collection from discharge database summaries (PMSI) Each year, the physician
serving as the study director will ask the Medical Information Department of each
healthcare facility to furnish a list of all women who were rehospitalized in the
42 days after giving birth or who had a surgical, or medical or interventional
radiology procedure during their postpartum stay. All of these records will be
studied manually by the investigator to check for cases of severe late PPH that
were not previously reported (quality control for case ascertainment).
6. Procedures to validate the cases of late PPH All reports of eligible women (that is, who
had a severe late PPH) will be checked at arrival by the investigator, who will verify
if this is the woman's first inclusion in the study. The investigator will verify the
woman's identity and date of birth during site visits, to avoid duplicate inclusions.
If it is a first inclusion, the investigator will validate the inclusion criteria before
submitting the file to one of the study directors, who will validate the etiological
diagnosis.
The investigator will verify the quality of the data collection and file completion: in
the case of missing data, he or she will take the steps required to have the data
completed at the reporting department.
The investigator will code the administrative items and drugs by using specific
thesauruses. The investigator will also enter the data for each record after coding,
using RedCap® software, available at the Clermont-Ferrand UHC.
A local index for each center, including the file number, if a file was opened, or
information about its status if it was not opened, the woman's first and last name, and
the reporting source will be maintained and kept up-to-date by the local investigator
for each late PPH diagnosis included.
7. Data analysis methods The α risk (of a type I error) will be set at 5%. The statistical
tests will be bilateral.
A descriptive analysis of the entire dataset will be performed. The incidence of severe
late PPH will be calculated with its 95% confidence interval.
A Cox model (with severe late PPH the variable to be explained) will be used to adjust
for the confounding factors or the clinically relevant prognostic factors for the onset
of severe late PPH. The point of origin will be the delivery. The model will make it
possible to calculate adjusted hazard ratios.
8. Patient information Patients will receive complete and fair information, expressed in
understandable terms, about the study objectives, the nature of the information
collected, and their right to object to at any point to the use of their data. The
investigator must also inform the patients of the Ethics Committee decision. Women will
be asked whether or not they object to participating in the study before their data are
collected.
All of this information will be included on an information sheet given to the woman to keep.
Her non-opposition will be collected and documented by the investigator.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 | |
Completed |
NCT02805426 -
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
|
Phase 4 | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 |